Clonal CD8⁺ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-09-01 DOI:10.3324/haematol.2023.284942

Roman Krzysiek, Samuel Bitoun, Rakiba Belkhir, Salima Hacein-Bey-Abina, Xavier Mariette

引用次数: 0

查看原文本刊更多论文

克隆 CD8+ T 细胞扩增与难治性多发性骨髓瘤患者对依拉那单抗的完全应答有关。

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.

Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma.

Clonal CD8⁺ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma.